Cargando…
Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal
ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently has no effective therapy. To date, clinically applicable targeted cancer therapy based on ARID1A mutational status...
Autores principales: | Biter, Benjamin G., Aird, Katherine M., Garipov, Azat, Li, Hua, Amatangelo, Michael, Kossenkov, Andrew V., Schultz, David C., Liu, Qin, Shih, Ie-Ming, Conejo-Garcia, Jose R., Speicher, David W., Zhang, Rugang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352133/ https://www.ncbi.nlm.nih.gov/pubmed/25686104 http://dx.doi.org/10.1038/nm.3799 |
Ejemplares similares
-
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity
por: Karakashev, Sergey, et al.
Publicado: (2018) -
SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells
por: Wu, Shuai, et al.
Publicado: (2018) -
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
por: Fukumoto, Takeshi, et al.
Publicado: (2018) -
ARID1A-mutated ovarian cancers depend on HDAC6 activity
por: Bitler, Benjamin G., et al.
Publicado: (2017) -
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
por: Mandal, Jayaprakash, et al.
Publicado: (2022)